Cost-effectiveness considerations in the treatment of essential thrombocythemia

Seminars in Oncology

Volumn 29, Issue 3, 2002, Pages 28-32

  Golub, Robert ^a,b   Adams, Jared ^a,b   Dave, Sundeep ^a,b   Bennett, Charles L ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; HYDROXYUREA; PARACETAMOL;

ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; ANOREXIA; CHILL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEVER; HEADACHE; HEART PALPITATION; HUMAN; HYPERPIGMENTATION; LEG ULCER; LIFE EXPECTANCY; MYALGIA; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW; SKIN CANCER; THROMBOCYTHEMIA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; COST-BENEFIT ANALYSIS; FIBRINOLYTIC AGENTS; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; NUCLEIC ACID SYNTHESIS INHIBITORS; QUINAZOLINES; THROMBOCYTOSIS;

EID: 0036300879     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(02)70150-4     Document Type: Article

References (17)

1. Anagrelide, a therapy for thrombocythemic states: Experience in 577 patients
2. The management of polycythaemia vera
3. Treatment of polycythemia vera
4. Anagrelide: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of thrombocythemia
5. Polycythemia vera
6. Anagrelide for the control of thrombocythemia in polycythemia and other myeloproliferative disorders
7. Multiple skin cancers associated with hydroxyurea therapy
8. Multiple skin tumors on light-exposed areas during long-term treatment with hydroxyurea
9. Multiple squamous-cell carcinomas of the scalp and chronic myeloid leukemia
10. Cutaneous carcinoma during long-term hydroxyurea therapy: A report of 5 cases
11. Hydroxyurea leg ulceration in 14 patients
12. Treatment of polycythemia vera: The use of hydroxyurea and pipobroman in 292 patients under the age of 65 years
13. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion
14. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG
15. Acute leukemia after hydroxyurea treatment in polycythemia vera and allied disorders: Prospective study of efficacy and leukemogenicity with therapeutic implications
16. Historical perspective on the treatment of essential thrombocythemia and polycythemia vera
17. Cost-effectiveness model of a phase II clinical trial of a new pharmaceutical for essential thrombocythemia: Is it helpful to policy makers?